drugset / Trial / NCT01452698

Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis

NCT01452698

Phase 3 Completed 409 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy of TAK-438, once daily (QD), compared to lansoprazole in patients with erosive esophagitis of Grade A to D as defined by the LA classification grading system.

Timeline

Start
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lansoprazole Other / unclassified 30 mg Oral
Subject Vonoprazan Other / unclassified 20 mg Oral
Subject Vonoprazan Other / unclassified 40 mg Oral

Indications